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Pharmacogenomics is the study of drug treatment responses in subgroups of patients on
the basis of their genetic variants or genetic expression information. In 2006, the govern-
ment of Taiwan launched a methadone maintenance treatment program, which is usually
prescribed for patients with heroin dependence. In this study, 366 patients who had taken
methadone continually in the previous 7 days were examined. Data from the Treatment
Outcomes Profile (TOP), Severity of Dependence Scale (SDS), Clinical Opioid Withdrawal
Scale (COWS), and Treatment Emergent Symptoms Scale (TESS) were obtained from the
patients’ report records. The genes CYP2B6, CYP3A4, and CYP2C19dwhich encode the liver
cytochrome P-450 (CYP) enzymes that are involved in the metabolism of methadonedwere
selected and genotyped in this cohort. We found that single nucleotide polymorphisms
(SNPs) on the CYP2B6 gene were associated with the plasma S-methadone concentration.
The SNPs on the CYP3A4 gene were associated with withdrawal symptoms and side effects.
The SNPs on the CYP2C19 gene were associated with the methadone dose. The SNPs in the
genes (e.g., UGT2B7) encoding the morphine phase II metabolic enzyme were associated
with the withdrawal symptom scores. In pharmacodynamic genes, the SNPs on the OPRM1
gene were associated with the side effects of insomnia and change in libido. We conclude
that SNP markers may be useful in the future for adjusting methadone dosage and for
reducing adverse reactions.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
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After administering a drug, the steady-state plasma drug
concentration may vary from individual to individual.
Research reports suggest that the steady-state plasma drug
concentrations may change from 5 to 10 times in males with a
body weight of approximately 70 kg [1]. If gender, age, and
pregnancy status are taken into consideration, the steady-state
plasma drug concentrations may vary 50e100 times. Based on
this result, it is impossible by using therapeutic drug moni-
toring to place patients in subgroups to examine treatment
responses. Pharmacogenomics attempts to use information
about an individual’s genomic make-up to place patients in
subgroups and match them with a more optimal medication
choice. This is a new field of pharmacology. Single nucleotide
polymorphism (SNP) is a genomicmarker that is often used for
subgrouping patients by their treatment responses.
A successful pharmacogenomics clinical trial requires a set
criteria. The most important criterion is to ensure the partici-
pating patients’ compliance during observation by research
nurses and during the measurement of the steady-state drug
concentrations. A well-designed clinical trial is another key to
achieving a successful pharmacogenomics study.
In 2006, the Taiwanese government established a metha-
done maintenance treatment (MMT) program. Since then,
more than 90 hospitals have provided MMT and more than
11,000 heroin-dependent patients have participated in this
program. The purpose of this program is to reduce heroin
abuse, reduce the spread of infectious diseases such as human
immunodeficiency virus (HIV) infection and hepatitis C virus
(HCV) infection, and reduce the drug-related crime rate.
Because individual methadone doses range from 5 mg/day to
180 mg/day, a drugedrug interaction may cause an overdose
and may induce lethal complications. Therefore, the National
Health Research Institutes (NHRI; Miaoli County, Taiwan)
launched a pharmacogenomics study in a MMT cohort.2. Methods
2.1. Study participants
This study was a cross-sectional methadone clinical trial. The
study was approved by the institutional review boards of the
National Health Research Institutes (Miaoli County, Taiwan)
and the following seven participating hospitals: Tao-Yuan
Mental Hospital (Taoyuan City, Taiwan); En-Chu-Kong Hos-
pital (New Taipei City, Taiwan); Far EasternMemorial Hospital
(New Taipei City, Taiwan); Taipei City Hospital, Song-De
Branch (Taipei, Taiwan) and Yang-Ming Branch (Taipei,
Taiwan); China Medical University Hospital (Taichung City,
Taiwan); and Wei Gong Memorial Hospital (Toufen, Taiwan).
Each study participant provided written, informed consent.
The project also was registered in the U.S. National Institutes
of Health Clinical Trial database (http://www. clinicaltrial.gov/
ct/show/NCT01059747).
We recruited 366 heroin-dependent individuals who were
undergoing MMT as outpatients. The inclusion criteria for
participants were: aged 18 years or older, being underMMT forat least 3 months with regular attendance in the previous 7
days, and a methadone dosage adjustment of no more than
10 mg in the previous 7 days. The exclusion criteria were:
comorbidity with other physical or mental disorders that
require immediate treatment or pregnancy.
2.2. Clinical assessments
The demographics, clinical characteristics, and methadone
treatment courses (e.g., dose, treatment duration, and treat-
ment adherence) for the previous week were obtained from
the patients’ report records [e.g., case report form (CRF)].
Information regarding the possible coadministration of other
medications in the previous week was obtained either from
the patients’ medical records or from the patients’ reports [2].
Prior to when methadone was administered, each patient
underwent several interviewer-administered assessments
such as: the Treatment Outcomes Profile (TOP), which mea-
sures the amount and frequency of alcohol and other illicit
substances used in the past 28 days [3]; the Severity of
Dependence Scale (SDS); and the Clinical Opioid Withdrawal
Scale (COWS), which measures the severity of 11 opioid
withdrawal symptoms [4].
Research nurses assessed methadone-related adverse
events by using the Treatment Emergent Symptoms Scale
(TESS), which consists of 43 treatment emergent symptoms
[5]. In this study, the patients only reported 31 symptoms.
Only symptoms that occurred after the initiation of MMTwere
counted asmethadone-related adverse events. The severity of
each symptomwas rated on a three-point Likert scale ranging
from mild (one point), moderate (two points), to severe (three
points).In the present study, only adverse events with a fre-
quency of 15% or higher were included in the analyses.
2.3. Serum and urine drug test
The levels of glutamate oxaloacetate transaminase (GOT;
reference range, less than 38 U/L), glutamic pyruvic trans-
aminase (GPT; reference range, less than 41 U/L), and gamma-
glutamyl transpeptidase (g-GT; reference range, 8e61 U/L)
from serum samples of patients were measured at the Taipei
Institute of Pathology (Taipei, Taiwan).
Urine specimens were collected prior to the administration
of methadone on the study day. A morphine screen test was
performed via a kinetic interaction of microparticles on the
Integra 800 device (Roche Diagnostics, Basel, Switzerland). In
our present analyses and in previous reports [2,6,7], the urine
morphine test was used as a surrogate measurement for the
methadone treatment outcome.
2.4. Analyses of methadone and its metabolites in the
plasma
Whole blood samples (12 mL) were obtained at approximately
24  2 h after the last methadone dose, when the plasma con-
centration ofmethadone is likely to be at its lowest. The plasma
concentrations of racemic methadone and its metabolite, 2-
ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), were
measured by using high-performance liquid chromatography
(HPLC) at the settings described in our previous study [8].
Table 1 e General demographics of the 366 methadone maintenance treatment patients.
Overall Urine morphine positive Urine morphine negative p
N ¼ 366 n ¼ 185 n ¼ 178
Mean  SD Mean  SD Mean  SD
Starting dose of methadone (mg/d) 32.04  11.15 31.64  10.07 32.44  12.22 0.77*
Current dose of methadone (mg/d) 54.67  28.12 54.53  26.07 55.32  30.13 0.88*
Age (y) 38.17  7.72 38.37  7.96 37.87  7.46 0.57*
Male 297 (81.2%) 152 (82.2%) 142 (79.8%) 0.56**
BMI (kg/m2) 23.58  3.52 23.62  3.57 23.59  3.49 0.89*
R-methadone concentration/methadone dose ratio 3.86  2.32 3.7  2.71 4.03  1.82 0.001*,***
S-methadone concentration/methadone dose ratio 2.77  1.57 2.58  1.45 2.98  1.66 0.012*,***
R-EDDP concentration/methadone dose ratio 0.31  0.5 0.26  0.33 0.33  0.54 0.26*
S-EDDP concentration/methadone dose ratio 0.33  0.49 0.31  0.38 0.33  0.58 0.95*
Human immunodeficiency virus infection 86 (24.0%) 50 (27.3%) 36 (20.8%) 0.15**
Hepatitis C virus infection 334 (94.9%) 173 (96.1%) 158 (93.5%) 0.27**
Data are presented as mean  SD or n (%).
* The p value is based on the Wilcoxon rank-sum test.
** The p value is based on the Chi-square test.
*** A p value < 0.05 is presented in bold font.
BMI ¼ body mass index; EDDP ¼ 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine.
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genotyping
The selection of SNPs was based on reports in the literature
[2,6,9e13], a minor allele frequency greater than 0.1 on the
HapMap in Chinese ethnic groups (http://hapmap.ncbi.nlm.
nih.gov/index.html.en), and possible functionalities predicted
by the bioinformatics tool FastSNP. This is not a kit. It is a paper
and also had an web-page for bioinformatics analyses [14].
Genomic DNA was extracted from the buffy coat of whole
blood lymphocyte pellets (6 mL) by using the Puregene Blood
Kit C (QIAGEN Sciences, Maryland, USA). Genotypes of the
selected 17 SNPswere identified by usingmatrix-assisted laser
desorption/ionization-time of flight mass spectrometry
(MALDI-TOF MS) [15]. This genotyping method has been uti-
lized in a broad variety of clinical applications because of the
accuracy of SNP detection, the sufficient sensitivity to score
SNPs from small amounts of template, the flexibility of the
procedure, and the cost effectiveness [16].
2.6. Statistics
All statistical analyseswereconductedbyusingSASversion9.1
software (SAS Institute, Inc., Cary, NC, USA). The Wilcoxon
rank-sum test (for continuous data) and the Chi-square test or
Fisher’s exact test (for categorical data) were applied for
comparing the clinical characteristics, theTESS scores, and the
COWS scores of patients testing positive for urine morphine
and patients testing negative for urine morphine. Association
analyses were calculated by using a generalized linear model
(GLM) procedure to compare the selected SNPswith eachof the
following: treatment outcomes, withdrawal symptoms, and
adverse events. The false discovery rate test of the MULTTEST
procedure was employed to correct for multiple hypotheses
tests of p values [17]. TheHardy-Weinberg equilibrium test and
haplotype block association analysis were performed by using
HAPLOVIEW version 4.1 software (Cambridge, MA, USA) [18]. A
statistical significance was a p < 0.05.3. Results
3.1. General clinical characteristics
One-half of the 366 MMT patients tested positive for urine
morphine (Table 1). The average age of these patients was
38.2  7.7 years and nearly all (99.5%) participants smoked
cigarettes. Males were predominant in this cohort (n ¼ 297;
81.1%). The average starting dose of methadone was
32  11 mg/day, and the dosage at the time of testing was
54.7  28 mg/day. The ratio of plasma R-methadone concen-
tration/methadone dose and the ratio of plasma S-methadone
concentration/methadone dose were higher in patients who
tested negative for urine morphine than in patients who
tested positive. The HCV incidence in these patients was 95%.
In body mass index and in test results for HIV and HCV
infection, there were no significant differences between pa-
tients who tested positive for urine morphine and patients
who tested negative for urine morphine.
The average COWS withdrawal symptom score was
1.49 1.86 points (Table 2). Therewas a statistically significant
higher incidence of bone and joint aches symptom scores in
patients testing positive for urine morphine (13% incidence
and 0.14 average score) than for patients who tested negative
for urine morphine (6.2% incidence and 0.08 average score).
Table 3 lists the top 15 side effects (based on percentage), as
rated by TESS. The side effect of impairedmentation showed a
significantly higher incidence in patients who tested positive
for urine morphine than in patients who tested negative
(22.2% vs. 20.8%, respectively).
3.2. Association analyses of pharmacokinetic genes and
methadone dose
Methadone is primarily metabolized in the liver through
specific isoforms of the cytochrome P-450 (CYP) enzyme sys-
tem [19]. These isoforms include CYP2B6, CYP2C19, and
Table 2 eWithdrawal symptoms of the 366 methadone maintenance patients.
Overall Urine Morphine Positive Urine Morphine Negative p p
N ¼ 366 N ¼ 185 N ¼ 178
n % Mean  SD n % Mean  SD n % Mean  SD
Sum of the COWS score 366 1.49  1.86 185 1.51  1.93 178 1.44  1.78 0.85*
Heart rate 365 77.55  11.86 184 76.83  11.29 178 78.20  12.24 0.37*
Sweating 41 11.20 0.13  0.40 26 14.10 0.17  0.48 14 7.90 0.08  0.30 0.06* 0.06**
Restlessness 24 6.60 0.07  0.25 15 8.10 0.08  0.27 8 4.50 0.04  0.21 0.16* 0.16**
Pupil size 69 18.90 0.21  0.46 34 18.50 0.20  0.44 35 19.70 0.22  0.48 0.74* 0.77**
Bone or joint aches 36 9.80 0.11  0.36 24 13.00 0.14  0.38 11 6.20 0.08  0.33 0.033*** 0.028**,***
Runny nose or tearing 31 8.50 0.11  0.39 14 7.60 0.10  0.36 17 9.60 0.13  0.43 0.49* 0.50**
Gastrointestinal upset 16 4.40 0.07  0.33 9 4.90 0.08  0.39 7 3.90 0.05  0.27 0.65* 0.67**
Tremor 39 10.70 0.15  0.46 20 10.80 0.13  0.40 19 10.70 0.17  0.53 0.91* 0.97**
Yawning 10 2.70 0.04  0.23 6 3.20 0.04  0.25 3 1.70 0.02  0.18 0.34* 0.50****
Anxiety or irritability 39 10.70 0.12  0.35 19 10.30 0.12  0.37 19 10.70 0.11  0.31 0.94* 0.90**
Gooseflesh skin 8 2.20 0.07  0.44 4 2.20 0.06  0.44 4 2.30 0.07  0.45 0.96* 1.00****
COWS ¼ Clinical Opiate Withdrawal Scale.
* The p value is based on the Wilcoxon rank-sum test.
** The p value is based on the Chi-square test.
*** A p value < 0.05 is presented in bold font.
**** The p value is based on Fisher’s exact test.
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different methadone enantiomers (Fig. 1). The R-form enan-
tiomer is preferably metabolized by CYP2C19 and the S-form
enantiomer is preferably metabolized by CYP2B6 [19]. In our
previous studies, the SNPs on CYP2B6 were significantly
associated with the plasma S-methadone concentration, the
S-methadone concentration/methadone dose ratio, and the S-
methadone clearance [6]. We also found that CYP2B6 has a
higher level of activity in HCV-positive patients. The SNPs in
CYP3A4 were significantly associated with the COWS score,
TESS score, and betel nut use [12]. As the withdrawalTable 3 e The top 15 side effects of the 366 methadone mainte
Overall Urine Morph
N ¼ 366 N ¼
n % Mean  SD n %
Constipation 248 67.80 1.96  0.84 125 67.60
Sedation 172 47.00 1.51  0.70 94 50.80
Change in libido 111 30.30 1.72  0.79 63 34.10
Dry mouth 101 27.60 1.55  0.70 59 31.90
Excessive sweating 71 19.40 1.86  0.85 38 20.50
Insomnia 67 18.30 1.93  0.78 32 17.30
Impaired mentation 79 21.60 1.61  0.72 41 22.20
Fatigue 65 17.80 1.62  0.78 32 17.30
Difficulty with urination 52 14.20 1.38  0.60 28 15.10
Increase in appetite 46 12.60 1.48  0.59 25 13.50
Decrease in appetite 44 12.00 1.55  0.70 26 14.10
Weight gain 38 10.40 1.68  0.74 18 9.70
Weakness 33 9.00 1.36  0.70 18 9.70
Malaise 27 7.40 1.48  0.64 13 7.00
Tachycardia/palpitations 25 6.80 1.44  0.71 14 7.60
* The p value is based on the Wilcoxon rank-sum test.
** The p value is based on the Chi-square test.
***A p value < 0.05 is presented in bold font.symptom scores increased, the side effect symptom score
increased, but betel nut use decreased. The gene dose of
CYP2C19 showed significant correlations with methadone
dose, R-methadone concentration/methadone dose ratio, and
R-EDDP concentration/methadone dose ratio [13]. The gene
dose was associated with the TESS scores in patients testing
positive for urine morphine. Patients who were extensive
metabolizers had a higher side effect score than patients who
were poor metabolizers.
The geneegene interaction association analyses indi-
cated that the CYP2C19 gene may not interact with CYP2B6nance patients.
ine Positive Urine Morphine Negative p * p **
185 N ¼ 178
Mean  SD n % Mean  SD
2.01  0.85 121 68.00 1.92  0.83 0.4 0.93
1.51  0.68 77 43.30 1.49  0.72 0.73 0.15
1.70  0.75 47 26.40 1.77  0.84 0.76 0.11
1.61  0.74 41 23.00 1.49  0.64 0.49 0.06
1.95  0.87 32 18.00 1.75  0.84 0.34 0.54
2.03  0.78 34 19.10 1.85  0.78 0.36 0.66
1.78  0.76 37 20.80 1.43  0.65 0.032*** 0.75
1.78  0.79 32 18.00 1.47  0.76 0.08 0.87
1.50  0.69 23 12.90 1.26  0.45 0.24 0.54
1.52  0.51 21 11.80 1.43  0.68 0.37 0.62
1.50  0.71 18 10.10 1.61  0.70 0.54 0.25
1.67  0.59 20 11.20 1.70  0.86 0.86 0.64
1.56  0.86 14 7.90 1.14  0.36 0.17 0.53
1.62  0.65 13 7.30 1.38  0.65 0.31 0.92
1.43  0.65 10 5.60 1.50  0.85 1.00 0.45
Fig. 1 e The methadone metabolic pathway. EEDP [ 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine.
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may allow the subgrouping of the methadone dose into six
dosage ranges and may increase the level of significant as-
sociations between the gene dose of CYP2C19 and the
methadone dose. In three-gene interaction association an-
alyses, CYP2C19 did not interact with either CYP2B6 or
CYP3A4. The allelic combination of CYP2B6 and CYP3A4
further subgrouped the methadone dose into 12 dose ranges
and increased the level of significant association between
CYP2C19 and the methadone dose from p ¼ 0.018 to p < 104.
This CYP2C19 interaction was also significantly associated
with methadone tolerance when defining it as the dose
difference between the current dose and the starting dose of
methadone.
In the phase II morphine metabolic enzyme UDP glucur-
onosyltransferase 2 family, polypeptide B7 (UGT2B7), the SNPs
in this coding region showed significant associations with the
severity of withdrawal symptom, as rated by the COWS scores
[7].3.3. Association analyses of the pharmacodynamic gene
OPRM1
The pharmacodynamic gene, OPRM1,was reported first in the
mu-opioid receptors. The nonsynonymous OPRM1 SNP
rs1799971 (exon 1, A118G polymorphism, Asn40Asp) showed a
marginally significant association with the methadone dose
(adjusted GLM; P ¼ 0.027). The intron 1 region of the SNPs
demonstrated significant associations with the side effects of
insomnia and change in libido [2]. It was also significantly
associated with the plasma nicotine metabolite cotinine [20].
In the recessive model of association analyses, the patients
who had a higher plasma cotinine level had a lower insomnia
symptom score. The pharmacokinetic genes may be corre-
lated with physical dependence, whereas the pharmacody-
namic genes are correlated to psychological dependence
(Fig. 2).4. Discussion
In this methadone maintenance cohort, we found that it is
impossible to explain heroin dependence by using a single
gene association analysis in pharmacogenomics studies. The
metabolism of methadone involves more than one single cy-
tochrome P-450 (CYP) enzyme (e.g., CYP2B6, CYP2C19, and
CYP3A4). The genetic variants of each CYP isozyme may play
different roles. The patients in this cohort were exposed to
multiple environmental influences (e.g., 95% patients tested
positive for the HCV antibody). All patients reported smoking
cigarettes. It is impossible to report these important envi-
ronmental influences with a single genetic association
analyses.
In the current study, especially in the pharmacokinetic
genesdthe interaction betweenCYP2C19, CYP2B6, and CYP3A4
may classify the patients into different methadone dosage
subgroups with a p value lower than the p value of the phar-
macodynamic OPRM1 single gene. This result indicated that
the requiredmethadone dosage is regulated by genes acting in
combination with pharmacokinetic and pharmacodynamic
influences. The SNPs in the pharmacokinetic genes (e.g.,
CYP2B6, CYP2C19, and CYP3A4) may be used as indicators for
the plasma methadone concentrations, the methadone dose,
and the severity of withdrawal symptoms.
The SNPs in the pharmacodynamic genes may influence
the dosage prediction and the treatment side effects. The
SNPs in the pharmacodynamic genes, especially the OPRM1
gene, were associated with the methadone dose and may be
predictors for methadone side effects such as insomnia and a
change in libido.
Pharmacogenomics studies promise the advent of
personalized medicine. In the association analyses of SNPs in
single genes, we found that each single gene covers a different
number of exons and introns. Using single genetic variants
may provide further information for genetic regulation and for
Fig. 2 e Pharmacogenomics study diagram for the methadone maintenance treatment patients.
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used to direct further biological study or be replicated in the
study of other ethnic groups.
The limitations of this cohort include a gender imbalance
(81% of the participants were male), a high prevalence of HCV
infection (95% of the participants were HCV positive), positive
results for urine morphine (approximately 50% of patients
tested positive), and the relatively small sample. Replication
studies are needed to establish future treatment guidelines.
Additional methods of optimizing drug therapy (with
respect to a patient’s genotype) warrant further investigation
to ensure maximum efficacy with minimal adverse effects.
This study took into consideration the potential of using a
single pharmacokinetics gene (e.g., CYP2B6, CYP3A4, CYP2C19,
UGT2B7, and PXR) and pharmacodynamic genes (e.g., OPRM1).
Studying random combinations of these genes and making
association analyses without having the results of each single
gene would not reveal the individual contributions of each
single gene in the systemic methadone treatment response.
Geneegene interaction should be based on single gene dis-
coveries, and not based on a nebulous theory. Because phar-
macogenomics studies are still at an early stage, it is essential
to study numerous SNP markers in each single gene, which
may represent the function of a gene. We therefore showed
the SNP IDs so that it would be easier for researchers who are
interested in replicating the study with other ethnic groups.
Methadone pharmacogenomics studies may decipher the
mechanisms of opioid dependence. There is great potential
for pharmacogenomics to be used as a clinical practice
guideline for future individualized medicine. Our studies
provide essential information in bridging the basic biologicalfunctional study through understanding the exon and intron
roles of each gene, and the potential drug targeting of novel
treatment processes through the association analyses of
treatment responses.
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